- Home
- MGTX vs LYEL Comparison
MGTX vs LYEL Comparison
Compare MGTX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$9.39
HOLD
Current Price
$23.32
Company Overview
Basic Information| Metric | MGTX | LYEL |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.1M | 490.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGTX | LYEL |
|---|---|---|
| Price | $9.39 | $23.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $22.86 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 593.3K | 79.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,391,000.00 | $36,000.00 |
| Revenue This Year | $118.35 | N/A |
| Revenue Next Year | N/A | $16,285.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $4.93 | $0.39 |
| 52 Week High | $9.88 | $45.00 |
Technical Indicators
Market Signals| Indicator | MGTX | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 57.88 |
| Support Level | $7.03 | $21.27 |
| Resistance Level | N/A | $27.30 |
| Average True Range (ATR) | 0.55 | 1.77 |
| MACD | 0.21 | 0.41 |
| Stochastic Oscillator | 82.57 | 94.23 |
Price Performance
Historical Comparison MGTX
LYEL
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.